MTNB - Matinas Biopharma - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

28.05M

Cash

22.51M

Avg Qtr Burn

-3.887M

Short % of Float

2.86%

Insider Ownership

2.92%

Institutional Own.

12.17%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
MAT2203 (Oral Amphotericin B) Details Meningitis, Cryptococcal meningitis, Azole-resistant infections, C. krusei infection, Fungal infections	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LYPDISO (MAT9001) (Omega-3 Drug) Details Cardiovascular disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.